60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a report released on Friday,Weiss Ratings reports.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research note on Tuesday, February 25th.

60 Degrees Pharmaceuticals Stock Performance

NASDAQ SXTP opened at $1.56 on Friday. The business has a fifty day moving average price of $3.74 and a 200 day moving average price of $5.23. 60 Degrees Pharmaceuticals has a one year low of $1.54 and a one year high of $35.99. The company has a market cap of $2.30 million, a P/E ratio of -0.15 and a beta of 4.52.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.